Radiographic and the Esthetic Outcome of Two Different Bone Grafting Techniques in Early Implant Placement

A Comparative, Randomized, Prospective, Clinical Study to Evaluate the Facial Bone and Esthetic Outcome of Buccal Augmentation Bone Grafting Techniques in Early (Type 2) Implant Placement

Total of 48 subjects were randomly assigned to treatment groups:

UT Health Science Center at San Antonio Chi Mei Medical Center, Tainan, Taiwan

Patients require a maxillary non-molar extraction site that is planned to be replaced by a dental implant and crown. This includes Straumann BL SLActive: Narrow (3.3mm) & Regular (4.1mm) Crossfit implants in all available lengths.

Patients were randomly selected to receive either FDBA (test) or Autogenous bone + DBBM (control/standard) for contour augmentation.

Study Overview

Detailed Description

This comparative, randomized, prospective clinical study is designed to compare clinical outcomes and facial bone height and thickness of two different bone grafting techniques after augmentation in (Type 2) early implant placement.

Human subjects who could potentially qualify with the said inclusion criteria will be evaluated and screened. 24 human subjects who qualify for the procedure will have a thorough evaluation performed after obtaining consent from the patient. All subjects will require extraction of maxillary teeth (incisors, canines, premolars), followed by early implant placement of the missing teeth after 4 to 8 weeks extraction.

There will be two subject groups in this study in which the 24 human subjects in will randomly be placed by selecting the number "1" or "2" from a hat. 24 human subjects will be divided into two groups including 12 subjects using control group design and 12 subjects using test group design. 12 subjects will be placed randomly into Group 1 and will undergo the flapless extraction and early implant placement with GBR procedure using the control group design. 12 subjects will be placed randomly into Group 2 and will undergo the flapless extraction and early implant placement with GBR procedure using the test group design.

During the implant placement visit after 4 to 8 weeks of extraction, patient will be asked to select a number from a hat. If the number showed "1" as a control group, autograft , BBM and collagen membrane will be used as GBR materials after implant placement. If the number showed "2" as a test group, FDBA and collagen membrane will be used as GBR materials after implant placement.

Extraction sites will include maxillary teeth (11,12,13,14,15,21,22,23,24,25 according to FDI) having intact adjacent teeth. Implants placed for this study will have a SLActive surface, bone level design, Straumann NC 3.3mm or RC 4.1mm in diameter at all available implant lengths.

Control group: early implant placement with autograft plus BBM (Bio-Oss, Geistlich Pharm AG, Wolhausen, Switzerland) plus two layers of collagen membrane (BioGide®).

Test group: early implant placement with FDBA (Straumann Allograft GC®) plus two layers of collagen membrane (BioGide®).

These procedures will follow the guidelines as described by Buser et al. (2008). Implant placements will follow standard protocols utilizing tapping and placement with the hand ratchet.

A CBCT radiograph will be made during the screening visit to determine eligibility for the study and immediately following implant placement with GBR procedure to provide facial bone height and thickness measurements. The second CBCT procedure is not typically a standard of care procedure. After 12 months post loading healing time, the patient will receive another CBCT. This CBCT is also not a standard of care procedure but can accurately assess the amount of facial bone height and thickness maintained during the follow-up period.

Study Type

Interventional

Enrollment (Actual)

48

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. The patient is 18 years or older.
  2. Non-smoker or patient has smoking habit and < 1 pack per day.
  3. Ability to understand and provide informed consent before starting the study.
  4. Ability and willingness to comply with all study requirements.
  5. The patient, if of child-bearing potential, has a negative urine pregnancy test.
  6. Adequate oral hygiene to allow for implant therapy consistent with standards of care.
  7. Adequate primary stability following early implant placement protocols utilizing Straumann Bone Level implants NC 3.3mm or RC 4.1mm in diameter at all available implant lengths.
  8. One or more teeth in maxilla (11,12,13,14,15,21,22,23,24,25 according to FDI) has been identified as having a hopeless prognosis requiring extraction leading to a single-tooth gap requiring implant placement as determined by clinician.
  9. Implant site that has a defect and requires bone augmentation. This will be determined by measuring on the CBCT image the available space for the implant and whether or not there is enough bone width where the implant is to be placed.

Exclusion Criteria:

  1. Patient reports current smoking habit > 1 pack per day or tobacco chewing use.
  2. History of alcoholism or drug abuse within the past 5 years.
  3. Severe bruxism or clenching habits.
  4. Patient has significant untreated periodontal disease (grade III or IV), caries, or clinical or radiographic signs of infection within two adjacent tooth positions of implant area.
  5. History of HIV infection, Hepatitis B or C.
  6. Patients with a history of systemic disease that precludes standard dental implant therapy.
  7. Presence of local inflammation or mucosal diseases such as lichen planus
  8. Patient history consistent with high risk for subacute bacterial endocarditis
  9. Current hematological disorder or coumadin (or similar) therapy
  10. Patient currently undergoing chemotherapy
  11. Patient history of radiation treatment to the head or neck
  12. Physical or mental handicaps that would interfere with patient's ability to exercise good oral hygiene on a regular basis
  13. Pregnant or breastfeeding women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control
Guided bone regeneration with Bovine Bone Mineral
Guided bone regeneration with Bovine Bone Mineral
Experimental: Experimental
Guided bone regeneration with freeze dried bone allograft
Guided bone regeneration with freeze dried bone allograft

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Facial bone thickness
Time Frame: Measured at 1 year post-loading
Facial bone thickness 1 year post-loading at 1, 3, and 5mm from the implant platform
Measured at 1 year post-loading

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in facial bone thickness
Time Frame: Between implant placement and 1 year post-loading
Change in facial bone thickness between implant placement and 1 year post-loading
Between implant placement and 1 year post-loading
mPI measurement
Time Frame: Measured at 6 and 12-months post-loading
Measurement of modified Plaque Index
Measured at 6 and 12-months post-loading
PD measurement
Time Frame: Measured at 6 and 12-months post-loading
Measurement of pocket depth
Measured at 6 and 12-months post-loading
mSBI measurement
Time Frame: Measured at 6 and 12-months post-loading
Measurement of modified sulcus bleeding index
Measured at 6 and 12-months post-loading
KM measurement
Time Frame: Measured at 6 and 12-months post-loading
Measurement of keratinized mucosa
Measured at 6 and 12-months post-loading

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 30, 2013

Primary Completion (Actual)

May 15, 2016

Study Completion (Actual)

May 15, 2016

Study Registration Dates

First Submitted

September 26, 2017

First Submitted That Met QC Criteria

September 29, 2017

First Posted (Actual)

October 4, 2017

Study Record Updates

Last Update Posted (Actual)

October 4, 2017

Last Update Submitted That Met QC Criteria

September 29, 2017

Last Verified

September 1, 2017

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fractured Tooth

Clinical Trials on Guided bone regeneration with Bovine Bone Mineral

3
Subscribe